Novo Nordisk Shares Face Geopolitical Headwinds from US Tariff Threat

Novo Nordisk investors are navigating a volatile mix of robust commercial performance and emerging political risk. While recent prescription data for a key new product exceeded expectations, a new trade dispute initiated by the United States against Denmark now casts a shadow over future margins and supply chain stability for the pharmaceutical giant.

Trade Policy Clash Overshadows Strong Product Launch

The market sentiment shifted sharply between Friday and Monday. The week ended on a high note following the release of IQVIA data showing a powerful debut for Novo Nordisk’s oral Wegovy tablet in the crucial US market. In the first four days of its launch, approximately 3,071 prescriptions were filled in US pharmacies. This significantly outpaced the roughly 1,900 prescriptions recorded for Eli Lilly’s competing drug, Zepbound, during a comparable initial phase. The data was interpreted as a clear signal that Novo Nordisk is successfully expanding its reach in the lucrative obesity treatment segment.

However, the opening of the new trading week brought a different narrative. Former US President Donald Trump announced plans to impose a 10% tariff on imports from Denmark, effective February 1, 2026, with a threat to raise it to 25% by June 1 of that year. The measure is explicitly tied to a diplomatic dispute concerning a potential purchase of Greenland. This development inadvertently places Danish corporations, with Novo Nordisk at the forefront, in the middle of a geopolitical conflict.

Assessing the Real Impact on Production and Margins

Market participants are now evaluating the potential financial impact of these proposed tariffs. Although Novo Nordisk is a Danish company, it has strategically expanded its US manufacturing footprint to mitigate cross-border risks. Its major facilities in Clayton, North Carolina, serve as a central pillar in the supply chain for GLP-1 medications like Wegovy.

Despite this, the company is not entirely insulated from trade policy shifts. A material portion of active pharmaceutical ingredients (APIs) and finished products are still manufactured in or shipped from Denmark. Analysts note that products labeled “Made in USA” would likely be exempt from tariffs, but other segments of the value chain could fall under the proposed duties. The net effect could be tangible “friction costs” within the supply chain.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

This uncertainty has dampened risk appetite within the Nordic C25 index, with Novo Nordisk shares acting as a barometer for broader market nervousness surrounding trade policy.

A Tale of Two Trading Sessions

The contrasting performance over two days highlights the current overlap of strong fundamentals and external political factors:

• Session One – Commercial Validation: Investors celebrated the successful rollout of oral Wegovy. The new format appeals to patients averse to injections, strengthening Novo’s defense against competitor Eli Lilly. The positive share price movement was a direct response to the robust prescription figures.
• Session Two – Political Overhang: The US tariff announcement introduced a risk factor that is difficult to quantify using traditional valuation models. A so-called “Greenland premium” is now being priced into Danish assets, affecting Novo Nordisk.

Despite recent fluctuations, the current share price of €50.34 remains notably above its 52-week low of €39.05, yet well below the high of €87.10—reflecting the stock’s high volatility over the past year. While the share has recovered significantly from its trough, it remains far from previous peaks.

Looking Ahead: Earnings and Tariff Clarification in Focus

Attention in the near term will center on how US investors interpret the pullback. Will the argument of substantial US-based production capacity be enough to partially offset the political risk, or will concerns over tariffs on Danish imports dominate sentiment?

A key fundamental event is already scheduled: Novo Nordisk will report its fourth-quarter 2025 results in early February. Management is expected to provide detailed commentary on the launch trajectory of the oral Wegovy pill and outline how the company plans to secure its supply chains and pricing structures should the US tariffs materialize. Until concrete decisions on the final shape of the punitive tariffs are made, investors should anticipate continued elevated volatility for Novo Nordisk shares.